Related references
Note: Only part of the references are listed.PIK3CA mutations, PTEN, and pHER2 expression and impact on outcome in HER2-positive early-stage breast cancer patients treated with adjuvant chemotherapy and trastuzumab
J. D. Jensen et al.
ANNALS OF ONCOLOGY (2012)
Insulin growth factor receptor-1 expression and loss of PTEN protein predict early recurrence in triple-negative breast cancer
Jabed Iqbal et al.
HISTOPATHOLOGY (2012)
mTOR Pathway Overactivation in BRAF Mutated Papillary Thyroid Carcinoma
Alexandra Faustino et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2012)
Everolimus in Postmenopausal Hormone-Receptor-Positive Advanced Breast Cancer
Jose Baselga et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
Jose Baselga et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Mechanisms of Endocrine Resistance in Breast Cancer
C. Kent Osborne et al.
ANNUAL REVIEW OF MEDICINE, VOL 62, 2011 (2011)
Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer
E. Razis et al.
BREAST CANCER RESEARCH AND TREATMENT (2011)
Targeting the Phosphatidylinositol 3-Kinase Signaling Pathway in Breast Cancer
Leonel F. Hernandez-Aya et al.
ONCOLOGIST (2011)
mTOR pathway activation in cutaneous melanoma is associated with poorer prognosis characteristics
H. Populo et al.
PIGMENT CELL & MELANOMA RESEARCH (2011)
PIK3CA Mutations Frequently Coexist with RAS and BRAF Mutations in Patients with Advanced Cancers
Filip Janku et al.
PLOS ONE (2011)
Status of PI3K inhibition and biomarker development in cancer therapeutics
B. Markman et al.
ANNALS OF ONCOLOGY (2010)
Phosphatidyl-inositol-3-kinase alpha catalytic subunit mutation and response to neoadjuvant endocrine therapy for estrogen receptor positive breast cancer
Matthew J. Ellis et al.
BREAST CANCER RESEARCH AND TREATMENT (2010)
Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer
Todd W. Miller et al.
JOURNAL OF CLINICAL INVESTIGATION (2010)
PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer
Sherene Loi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Protocol for PTEN Expression by Immunohistochemistry in Formalin-fixed Paraffin-embedded Human Breast Carcinoma
Rita A. Sakr et al.
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY (2010)
Role of biologic therapy and chemotherapy in hormone receptor- and HER2-positive breast cancer
A. U. Buzdar
ANNALS OF ONCOLOGY (2009)
PIK3CA and PIK3CB Inhibition Produce Synthetic Lethality when Combined with Estrogen Deprivation in Estrogen Receptor-Positive Breast Cancer
Robert J. Crowder et al.
CANCER RESEARCH (2009)
S6 Kinase 1 Regulates Estrogen Receptor α in Control of Breast Cancer Cell Proliferation
Rachel L. Yamnik et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)
Targeting the phosphoinositide 3-kinase pathway in cancer
Pixu Liu et al.
NATURE REVIEWS DRUG DISCOVERY (2009)
Integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer
Katherine Stemke-Hale et al.
CANCER RESEARCH (2008)
Phosphatidylinositol 3-Kinase Hyperactivation Results in Lapatinib Resistance that Is Reversed by the mTOR/Phosphatidylinositol 3-Kinase Inhibitor NVP-BEZ235
Pieter J. A. Eichhorn et al.
CANCER RESEARCH (2008)
PIK3CA gene amplification in Japanese non-small cell lung cancer
Osamu Kawano et al.
LUNG CANCER (2007)
A transforming mutation in the pleckstrin homology domain of AKT1 in cancer
John D. Carpten et al.
NATURE (2007)
PIK3CA mutations and PTEN loss correlate with similar prognostic factors and are not mutually exclusive in breast cancer
Gizeh Perez-Tenorio et al.
CLINICAL CANCER RESEARCH (2007)
Clinicopathologic analysis of breast cancers with PIK3CA mutations in Japanese women
Naomi Maruyama et al.
CLINICAL CANCER RESEARCH (2007)
PIK3CA alterations in primary (de novo) and secondary glioblastomas
Daisuke Kita et al.
ACTA NEUROPATHOLOGICA (2007)
PIK3CA mutations in breast cancer are associated with poor outcome
SY Li et al.
BREAST CANCER RESEARCH AND TREATMENT (2006)
Mutation of the PIK3CA oncogene in human cancers
B Karakas et al.
BRITISH JOURNAL OF CANCER (2006)
Exploiting the PI3K/AKT pathway for cancer drug discovery
BT Hennessy et al.
NATURE REVIEWS DRUG DISCOVERY (2005)
Inhibition of mTOR and estrogen receptor signaling in vitro induces cell death in models of breast cancer
A Boulay et al.
CLINICAL CANCER RESEARCH (2005)
PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma
LH Saal et al.
CANCER RESEARCH (2005)
Reduced PTEN expression predicts relapse in patients with breast carcinoma treated by tamoxifen
N Shoman et al.
MODERN PATHOLOGY (2005)
Somatic mutation and gain of copy number of PIK3CA in human breast cancer
GJ Wu et al.
BREAST CANCER RESEARCH (2005)
High frequency of mutations of the PIK3CA gene in human cancers
Y Samuels et al.
SCIENCE (2004)
Reduced PTEN expression is associated with poor outcome and angiogenesis in invasive ductal carcinoma of the breast
JS Lee et al.
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY (2004)
Mutation of the PIK3CA gene in ovarian and breast cancer
IG Campbell et al.
CANCER RESEARCH (2004)
Phosphoinositide 3-kinase signalling - which way to target?
MP Wymann et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2003)
Loss of expression of the PTEN gene protein product is associated with poor outcome in breast cancer
PL Depowski et al.
MODERN PATHOLOGY (2001)
Share Paper
